A Randomized, Phase II Trial of AZD2171, Docetaxel, and Prednisone Compared to Docetaxel and Prednisone in Patients with Metastatic, Hormone Refractory Prostate Cancer. (NCI Protocol 7451)
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Cediranib (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 14 Apr 2015 Status changed active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 16 Feb 2013 Secondary efficacy and tolerability results presented at the 2013 Genitourinary Cancers Symposium.
- 16 Feb 2013 Due to grade IV neutropenia, the dosage of cediranib was reduced from 30 to 20 mg/day.